Abstract：
BACKGROUND: Myelosuppression, a challenge in cancer treatment, often results in severe complications. Prophylactic granulocyte colony-stimulating factors, particularly pegfilgrastim, mitigate chemotherapy-induced neutropenia. This narrative review evaluates the role of on-body injector (OBI) devices for pegfilgrastim administration. A comprehensive search strategy of PubMed and AI-powered intuitive search tools, complemented by authors\' contributions, yielded a body of papers presenting evidence on OBI devices, their effectiveness and safety, the benefits and challenges of OBI versus pre-filled syringe administration, patient preferences for pegfilgrastim administration, and economic considerations.
CONCLUSIONS: OBI devices prove effective and safe, with advantages such as reduced clinic visits and enhanced adherence. Studies highlight cost-efficiency and expanded access, emphasizing the socioeconomic context. Patient and provider preferences underscore the potential of OBI devices in cancer care, with implications for healthcare resource utilization and pharmacoeconomics.
CONCLUSIONS: The value proposition of OBI devices lies in improving patient outcomes, convenience, resource optimization, and enhancing the overall cancer care experience. As biosimilar OBIs enter the market, they may offer cost savings, further influencing their adoption and their positioning as a cost-efficient alternative in cancer care. Ongoing research and technological advancements are expected to contribute to the broader acceptance of OBI devices in cancer care delivery.
CONCLUSIONS: OBI devices prove effective and safe, with advantages such as reduced clinic visits and enhanced adherence. Studies highlight cost-efficiency and expanded access, emphasizing the socioeconomic context. Patient and provider preferences underscore the potential of OBI devices in cancer care, with implications for healthcare resource utilization and pharmacoeconomics.
CONCLUSIONS: The value proposition of OBI devices lies in improving patient outcomes, convenience, resource optimization, and enhancing the overall cancer care experience. As biosimilar OBIs enter the market, they may offer cost savings, further influencing their adoption and their positioning as a cost-efficient alternative in cancer care. Ongoing research and technological advancements are expected to contribute to the broader acceptance of OBI devices in cancer care delivery.
摘要：
背景：骨髓抑制，癌症治疗的挑战，常导致严重的并发症。预防性粒细胞集落刺激因子，尤其是pegfilgrastim,减轻化疗诱导的中性粒细胞减少症。这篇叙述性综述评估了体内注射器（OBI）设备在pegfilgrastim管理中的作用。PubMed和AI驱动的直观搜索工具的全面搜索策略，辅以作者的贡献，发表了一系列关于OBI设备的证据，它们的有效性和安全性，OBI与预填充注射器给药的好处和挑战，患者对pegfilgrastim给药的偏好，和经济考虑。
结论：OBI设备证明是有效和安全的，具有减少诊所就诊次数和提高依从性等优势。研究强调了成本效益和扩大的访问，强调社会经济背景。患者和提供者的偏好强调了OBI设备在癌症护理中的潜力，对医疗资源利用和药物经济学有影响。
结论：OBI设备的价值主张在于改善患者预后，便利性，资源优化，并增强整体癌症护理体验。随着生物类似药OBI进入市场，他们可以节省成本，进一步影响他们的采用和他们在癌症治疗中作为一种具有成本效益的替代方案的定位。正在进行的研究和技术进步预计将有助于OBI设备在癌症护理交付中的更广泛接受。
结论：OBI设备证明是有效和安全的，具有减少诊所就诊次数和提高依从性等优势。研究强调了成本效益和扩大的访问，强调社会经济背景。患者和提供者的偏好强调了OBI设备在癌症护理中的潜力，对医疗资源利用和药物经济学有影响。
结论：OBI设备的价值主张在于改善患者预后，便利性，资源优化，并增强整体癌症护理体验。随着生物类似药OBI进入市场，他们可以节省成本，进一步影响他们的采用和他们在癌症治疗中作为一种具有成本效益的替代方案的定位。正在进行的研究和技术进步预计将有助于OBI设备在癌症护理交付中的更广泛接受。
